Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Pivotal Study of BCB-276, a B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma

NCT07680439 is registered in ClinicalTrials.gov with BrainChild Bio, Inc as lead sponsor.

NCT NCT07680439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Pivotal Study of BCB-276, a B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma
Lead sponsor
BrainChild Bio, Inc
Phase
Phase 2
Overall status
Recruiting
Start date
August 31, 2026
Completion date
July 31, 2030
Enrollment
75 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adult cancer patients, brain tumor, brainstem glioma, central nervous system tumor, cns tumor, cns tumor, adult, cns tumor, childhood, diffuse intrinsic pontine glioma, diffuse midline glioma, dipg, dmg, pediatric cancer